News

Infants, teens and young adults treated with Spinraza show improved motor function

Infants, teens and young adults treated with Spinraza show improved motor functionNew Data presented at the Muscular Dystrophy Association’s clinical conference show benefit in motor function for infants, teens and young adults treated with Spinraza™ (nusinersen).

The NURTURE study results reported that all study participants (25 infants) were alive and experienced improved motor function at the time of reporting, compared to a decline seen in SMA natural history.

One-hundred percent of NURTURE participants achieved the age-expected World Health Organisation motor milestone of sitting without support, a development never seen with SMA Type 1.

Case series conducted on Spinraza-treated teens and young adults with SMA Type 2 and 3 (17 to 19 years old upon their last visit) demonstrated stable or improved motor function and improved quality of life.

Spinraza™ is the first treatment for SMA. It was approved for the treatment of all SMA Types by the European Commission on 1st June 2017, after recommendation by the European Medicines Agency.

More information

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.